Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Indomethacin attenuates the hypotensive action of hydralazine. Clin Pharmacol Ther 1986 May;39(5):564-70 PMID: 3698464

Pubmed ID



To determine whether indomethacin affects the vasodilator action of hydralazine in man, we studied nine healthy human subjects in a crossover, double-blind, randomized trial. Subjects received either oral indomethacin (200 mg) or placebo, after which they received two 0.15 mg/kg doses of intravenous hydralazine given 30 minutes apart. During the placebo phase there was a prompt hypotensive response after the first dose of hydralazine, with concomitant increases in heart rate, renal blood flow, and plasma norepinephrine and epinephrine levels but no consistent changes in forearm blood flow or vascular resistance. In contrast, the hypotensive response in the indomethacin phase occurred only after the second dose of hydralazine, and the magnitude of change in blood pressure was less than that in the placebo phase. The effects of hydralazine on heart rate, renal blood flow, limb blood flow, and plasma catecholamine levels were not affected by indomethacin. These results suggest that prostaglandins do play a role in the medication of the vasodilator effects of hydralazine, because its hypotensive effect was attenuated by indomethacin. However, this interaction must occur in vascular beds other than the limb or renal circulations, where no effect of indomethacin was observed.

Author List

Cinquegrani MP, Liang CS


Michael P. Cinquegrani MD Director, Professor in the Medicine department at Medical College of Wisconsin


2-s2.0-0022577270   20 Citations

MESH terms used to index this publication - Major topics in bold

Analysis of Variance
Blood Pressure
Double-Blind Method
Drug Interactions
Glomerular Filtration Rate
Heart Rate
Infusions, Parenteral
Random Allocation
Renal Circulation
Vascular Resistance
jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70